The verdict
Our read at a glance.
Whether nesiritide's early approval and plausible mechanism in acute heart failure were borne out by later outcomes evidence.
- The signal
- Early approval rested on improvement in shortness of breath and hemodynamics. The large ASCEND-HF trial later found nesiritide did not meaningfully improve key outcomes, and earlier concerns about kidney function and survival had already reduced enthusiasm. Use declined and the product was discontinued.
- The unknown
- Little remains in active question, since the product is discontinued. The lasting lesson is how early surrogate improvements failed to predict outcomes.
- Our read
- A cautionary tale, not a current treatment. Nesiritide looked promising and was approved, but a large trial showed little real benefit and the product was discontinued, a clear example of why approval and plausibility are not the same as proven outcomes.
The mechanism
How it works.
Nesiritide is a recombinant copy of human B-type natriuretic peptide (BNP), the hormone the heart secretes when its walls are stretched by excess pressure or volume. It binds the natriuretic peptide receptor A on blood vessels and kidney cells, which raises cyclic GMP inside those cells, relaxing the vessel walls and prompting the kidneys to shed sodium and water. Widening the vessels and offloading fluid lowers the pressure the failing heart has to pump against, which was the rationale for using it in acute decompensated heart failure.
Safety & regulatory boundary
The consequential part.
Nesiritide can cause low blood pressure, and earlier analyses raised questions about kidney function and survival before the large neutral trial. The Natrecor product has been discontinued, so current nesiritide is not a routinely available approved therapy. It should not be treated as a recommended heart-failure treatment, and any compounded or research-labeled nesiritide is not the approved product.
What's next
What we're watching.
Mostly of historical interest. Any renewed natriuretic-peptide approaches would need their own outcomes evidence.
Context
Why this is discussed.
Nesiritide is a well-known cautionary tale in cardiology about a biologically plausible, approved drug whose benefit did not hold up in a large trial.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2024-09-30
ClinicalTrials.gov · PHASE2 · COMPLETED · 2025-06-02
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-05-06
ClinicalTrials.gov · PHASE2/PHASE3 · RECRUITING · 2023-05-31
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-05
ClinicalTrials.gov · PHASE2/PHASE3 · ACTIVE_NOT_RECRUITING · 2023-03-07
ClinicalTrials.gov · PHASE3 · TERMINATED · 2018-12-21
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-06-19
Indexed literature (PubMed)12
Martindale JL et al. · Acad Emerg Med · 2016
Ammar LA et al. · Heart Fail Rev · 2025
Hall C · J Card Fail · 2005
Potter LR et al. · Handb Exp Pharmacol · 2009
Romero-Cabrera JL et al. · Int J Mol Sci · 2022
McLellan J et al. · BMJ Evid Based Med · 2020
Su X et al. · Int J Chron Obstruct Pulmon Dis · 2023
Gupta V et al. · Oral Dis · 2026
White M et al. · Med Sci (Basel) · 2021
Jeong SH et al. · Medicine (Baltimore) · 2024
Diaz-Arocutipa C et al. · Clin Cardiol · 2022
Li AT et al. · Ann Surg · 2022
Keep reading